Avelumab in gastric cancer

Area of Science:

• Oncology
• Immunotherapy
• Gastroenterology

Background:

• Gastric cancer (GC) is a leading cause of cancer death globally, with poor prognosis in metastatic stages.
• Current treatments like surgery and chemotherapy have limitations for advanced GC.
• Avelumab, an anti-PD-L1 antibody, is approved for other cancers and is being investigated for GC.

Purpose of the Study:

• To review the chemical structure and pharmacologic properties of avelumab.
• To summarize the current efficacy data of avelumab in gastric cancer treatment from clinical trials.
• To describe ongoing studies evaluating avelumab in GC, alone or in combination therapies.

Main Methods:

• Literature review of published data on avelumab.
• Analysis of clinical trial results (Phase I, II, and ongoing) for gastric cancer treatment.
• Examination of avelumab's mechanism of action and pharmacological profile.

Main Results:

• Avelumab's structure and properties relevant to cancer therapy are detailed.
• Clinical trial data on avelumab's efficacy in gastric cancer is presented.
• Ongoing trials exploring avelumab's use in various GC settings are highlighted.

Conclusions:

• Avelumab demonstrates potential as a therapeutic option for gastric cancer.
• Further clinical investigation is warranted to establish its role in GC treatment.
• Combination strategies involving avelumab may offer improved outcomes for GC patients.